Breast tumor stroma: A driving force in the development of resistance to therapies
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common cancer and the second leading cause of cancer‐related death in women worldwide. In spite of huge advancements in early detection and ever‐increasing knowledge of breast cancer biology, approximately 30% of patients with early‐stage breast cancer experience disease recurrence. Most patients are chemosensitive and cancer free immediately after the treatment. About 50% to 70% of breast cancer patients, however, will relapse within 1 year. Such a relapse is usually concomitant with adenocarcinoma cells acquiring a chemoresistant phenotype. Both de novo and acquired chemoresistance are poorly understood and present a major burden in the treatment of breast cancer. Although, previously, chemoresistance was largely linked to genetic alterations within the cancer cells, recent investigations are indicating that chemoresistance can also be associated with the tumor microenvironment. Nowadays, it is widely believed that tumor microenvironment is a key player in tumor progression and response to treatment. In this study, we will review the interactions of breast tumor cells with their microenvironment, present the latest research on the resistance mediated by the stromal component in breast cancer, and discuss the potential therapeutic strategies that can be exploited to treat breast cancers by targeting tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. (2015) · BMC Medicine · doi:10.1186/s12916-014-0241-z · Cited by 1,927
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
Gabbiani, G., Ryan, G. B., & Majno, G. (1971) · Experientia · doi:10.1007/bf02147594 · Cited by 1,485
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion
Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y. Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3323 · Cited by 1,134
Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage.
Karimian, A., Ahmadi, Y., & Yousefi, B. (2016) · DNA Repair · doi:10.1016/j.dnarep.2016.04.008 · Cited by 1,110
Self-citationCarcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Tumor-Associated Macrophages Press the Angiogenic Switch in Breast Cancer
Lin, E. Y., & Pollard, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0912 · Cited by 463
Liao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007965 · Cited by 437
The Evolution of Extracellular Matrix
Özbek, S., Balasubramanian, P. G., Chiquet-Ehrismann, R., Tucker, R. P., & Adams, J. C. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-03-0251 · Cited by 347
Roodhart, J. M. L., Daenen, L. G. M., Stigter, E. C. A., Prins, H.-J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J. G., van Amersfoort, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.010 · Cited by 305
Cited by
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 399
Mierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 262
Modulating tumor hypoxia by nanomedicine for effective cancer therapy
Jahanban‐Esfahlan, R., de la Guardia, M., Ahmadi, D., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25859 · Cited by 201
“In addition, the ManHA-MnO2 treatment significantly inhibited HIF-1α and VEGF expression, and markedly boosted tumor oxygenation and CT performance in breast tumors (Majidinia & Yousefi, 2017).”
BackgroundSelf-citationCombination of nanotechnology with vascular targeting agents for effective cancer therapy
Jahanban‐Esfahlan, R., Seidi, K., Banimohamad‐Shotorbani, B., Jahanban‐Esfahlan, A., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26051 · Cited by 84
Self-citationOrganotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening
Ferreira, L. P., Gaspar, V. M., Mendes, L., Duarte, I. F., & Mano, J. F. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120983 · Cited by 59
Metadata
- Authors
- Majidinia, M., & Yousefi, B.
- Venue
- Chemical Biology & Drug Design
- Publisher
- Wiley
- Published
- 2017-01-02
- Volume
- 89
- Issue
- 3
- Pages
- 309-318
- ISSN
- 1747-0277 (ISSN-L)
- 1747-0285
- OpenAlex
- W2562636094
- Cited by
- 68
- References
- 19
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.